Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Diabetes stories

Apr 13, 2026

Genetic Variants Explain Why GLP-1 Drugs Like Ozempic Don't Work for 10% of Patients

New research reveals that approximately 10% of people carry specific genetic variants that make popular diabetes and weight-loss drugs like Ozempic and Wegovy significantly less effective, providing the first genetic explanation for variable drug response.

Apr 13, 2026·1 source
00

Top claims

  • ▪Experiments with collaborators in Copenhagen showed that the PAM defect does not affect how GLP-1 binds to its receptor or how signals are transmitted.
  • ▪Two additional clinical trials funded by pharmaceutical companies showed no difference in response between PAM variant carriers and non-carriers when using longer-acting GLP-1 drugs.
  • ▪In a combined analysis of three clinical trials with 1,119 participants, individuals with PAM variants responded less effectively to GLP-1 drugs and were less likely to reach target HbA1c levels.

Topics

Supplementation fundamentalsMetabolic healthGLP-1 medicationsBiomarkers & bloodwork testingNutrition fundamentals
Blood sugar & insulin

Related entities

OzempicWeight lossGenetic

Featured Stories

OpenAI pauses development of Astra AI model over critical cybersecurity capability concerns

OpenAI pauses development of Astra AI model over critical cybersecurity capability concerns

Aug 7, 2026·2 sources